evo真人视讯

Brief News | Chairman Shi Yuanyuan Inspects the Construction Progress of Shenzhen Cell Valley – South China Cell Factory Project

Date:01-10  Hits:  Belong to:News


图片.png

On the morning of January 9, 2023, Shi Yuanyuan, Chairman of Shenzhen Cell Valley, visited the construction site of the Shenzhen Cell Valley – South China Cell Factory project to inspect the progress of the project. Assistant to the Chairman Wei Zheng and Director of the General Administration Office Luan Zhishi accompanied the visit.

图片.png

The construction of the South China Cell Factory project is proceeding on schedule, with close coordination among all parties involved. The project is expected to be completed on February 28, 2023, with official occupancy planned for March. Chairman Shi Yuanyuan emphasized the importance of maintaining a strong awareness of production safety and strengthening the safety defense line. He stressed that all work must be carried out in accordance with requirements, standards, and plans to ensure the orderly progress of the project, the smooth and steady advancement of all construction activities, and the earliest possible commencement of production and operations.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@rodael.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software